Association Between Elevated Lipoprotein(a) and Diastolic Dysfunction: A Retrospective Cohort Study
- PMID: 40663316
- DOI: 10.1007/s40292-025-00727-8
Association Between Elevated Lipoprotein(a) and Diastolic Dysfunction: A Retrospective Cohort Study
Abstract
Introduction: Lipoprotein(a) [Lp(a)] has been linked to myocardial fibrosis and endothelial dysfunction, proposed mechanisms for diastolic dysfunction (DD). This study assessed the association between elevated Lp(a) (≥ 50 mg/dL) and DD in patients with preserved ejection fraction (EF).
Aim: We analyzed 1492 adults (median age59) with an Lp(a) measurement and echocardiogram (1997-2024).
Methods: Diastolicdysfunction required ≥ 3 abnormal echo parameters, as per recent guidelines. Logisticregression adjusting for potential confounders was performed.
Results: Seventy-sevenpatients (5.1%) had DD. Lp(a) ≥ 50 mg/dL was not associated with DD [adjusted oddsratio (aOR): 0.89, 95% confidence interval (CI): 0.49-1.54]. However, age (aOR:1.03, p = 0.026), hypertension (aOR: 1.83, p = 0.042), diabetes mellitus (aOR: 2.43, p =0.002), and cardiovascular (CV) diseases (aOR: 1.90, p = 0.043) were associated withDD, while statin therapy was associated with reduced risk (aOR: 0.51, p = 0.016).
Conclusions: In the setting of preserved EF, Lp(a) was not associated with DD,emphasizing management of traditional CV risks.
Keywords: Cardiovascular; Cholesterol; Diastolic dysfunction; Lipoprotein.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors have no competing interests to declare that are relevant to the content of this article. Ethical approval: The study was approved by the Mayo Clinic Institutional Review Board, with informed consent waived due to its retrospective nature.
References
-
- Marcovina SM. Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease. Crit Rev Clin Lab Sci. 2023;60(8):560–72.
-
- Arsenault BJ, Kamstrup PR. Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective. Atherosclerosis. 2022;349:7–16.
-
- Chung CS, Shmuylovich L, Kovacs SJ. What global diastolic function is, what it is not, and how to measure it. Am J Physiol Heart Circ Physiol. 2015;309(9):H1392–406.
-
- Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.
-
- Chehab O, Abdollahi A, Whelton SP, Wu CO, Ambale-Venkatesh B, Post WS, Bluemke DA, Tsai MY, Lima JAC. Association of Lipoprotein(a) levels with myocardial fibrosis in the multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2023;82(24):2280–91.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous